Welcome to our dedicated page for SeaStar Medical SEC filings (Ticker: ICUCW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SeaStar Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SeaStar Medical's regulatory disclosures and financial reporting.
SeaStar Medical Holding Corporation reported a quarterly net loss of $3.5 million on $0.5 million of revenue for the three months ended March 31, 2026. Revenue rose from $0.3 million a year earlier as QUELIMMUNE pediatric therapy adoption increased, but spending on research and development ($2.3 million) and general and administrative costs ($1.7 million) kept the company unprofitable.
Cash totaled $9.3 million with total assets of $11.3 million and an accumulated deficit of $155.2 million. Management states that existing cash will not fund operations for at least 12 months, raising substantial doubt about the company’s ability to continue as a going concern. SeaStar highlights ongoing commercialization of QUELIMMUNE, pivotal NEUTRALIZE-AKI and other adult trials, and notes a dismissed securities class action and a pending derivative suit.
SeaStar Medical Holding Corporation reported a quarterly net loss of $3.5 million on $0.5 million of revenue for the three months ended March 31, 2026. Revenue rose from $0.3 million a year earlier as QUELIMMUNE pediatric therapy adoption increased, but spending on research and development ($2.3 million) and general and administrative costs ($1.7 million) kept the company unprofitable.
Cash totaled $9.3 million with total assets of $11.3 million and an accumulated deficit of $155.2 million. Management states that existing cash will not fund operations for at least 12 months, raising substantial doubt about the company’s ability to continue as a going concern. SeaStar highlights ongoing commercialization of QUELIMMUNE, pivotal NEUTRALIZE-AKI and other adult trials, and notes a dismissed securities class action and a pending derivative suit.
SeaStar Medical Holding Corporation reports that, as of March 31, 2026, the reporting parties may be deemed to beneficially own 443,253 shares of Common Stock, representing 9.99% of the class based on 3,993,719 shares outstanding as of March 24, 2026. The reported position consists of four warrants held by Intracoastal exercisable for 134,615, 134,615, 131,062 and 42,961 shares, and excludes additional warrants subject to blocker provisions. Without the blocker provisions, the reporting persons may have been deemed to beneficially own 534,285 shares.
SeaStar Medical Holding Corporation reports that, as of March 31, 2026, the reporting parties may be deemed to beneficially own 443,253 shares of Common Stock, representing 9.99% of the class based on 3,993,719 shares outstanding as of March 24, 2026. The reported position consists of four warrants held by Intracoastal exercisable for 134,615, 134,615, 131,062 and 42,961 shares, and excludes additional warrants subject to blocker provisions. Without the blocker provisions, the reporting persons may have been deemed to beneficially own 534,285 shares.
SeaStar Medical reported first quarter 2026 results showing early commercial traction but continued losses. Net revenue reached $0.5 million, up from $0.3 million a year earlier, driven by sales of its QUELIMMUNE pediatric AKI therapy and a 69% year-over-year revenue increase.
The company added seven top-rated children’s hospitals to its QUELIMMUNE customer base and advanced enrollment in the NEUTRALIZE-AKI pivotal trial in adults with acute kidney injury. SeaStar recorded a net loss of $3.5 million, slightly improved from a $3.8 million loss in the prior-year quarter.
Research and development expenses were $2.3 million and general and administrative expenses were $1.7 million, both roughly flat versus last year. Cash was $9.3 million as of March 31, 2026, down from $12.0 million at year-end, reflecting ongoing operating cash use as the company invests in commercialization and its adult AKI trial.
SeaStar Medical reported first quarter 2026 results showing early commercial traction but continued losses. Net revenue reached $0.5 million, up from $0.3 million a year earlier, driven by sales of its QUELIMMUNE pediatric AKI therapy and a 69% year-over-year revenue increase.
The company added seven top-rated children’s hospitals to its QUELIMMUNE customer base and advanced enrollment in the NEUTRALIZE-AKI pivotal trial in adults with acute kidney injury. SeaStar recorded a net loss of $3.5 million, slightly improved from a $3.8 million loss in the prior-year quarter.
Research and development expenses were $2.3 million and general and administrative expenses were $1.7 million, both roughly flat versus last year. Cash was $9.3 million as of March 31, 2026, down from $12.0 million at year-end, reflecting ongoing operating cash use as the company invests in commercialization and its adult AKI trial.
SeaStar Medical Holding Corporation ownership disclosure: Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri each report beneficial ownership of 278,436 shares of common stock issuable upon exercise of warrants. This holding represents 6.52% of the class based on 3,993,719 shares outstanding as of March 24, 2026. The issuable shares are subject to a 9.99% beneficial ownership blocker. The reported holdings are stated as of March 31, 2026.
SeaStar Medical Holding Corporation ownership disclosure: Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri each report beneficial ownership of 278,436 shares of common stock issuable upon exercise of warrants. This holding represents 6.52% of the class based on 3,993,719 shares outstanding as of March 24, 2026. The issuable shares are subject to a 9.99% beneficial ownership blocker. The reported holdings are stated as of March 31, 2026.
SeaStar Medical Holding Corporation is asking stockholders to vote at its virtual 2026 annual meeting on four key items. Stockholders will elect one Class I director, John Neuman, to serve until the 2029 annual meeting, and vote on an expanded equity plan.
The company seeks approval to amend and restate its 2022 Equity Incentive Plan to increase authorized common shares under the plan from 207,046 to 896,546, following a 1-for-10 reverse stock split effective January 5, 2026. Stockholders will also vote on ratifying WithumSmith+Brown, PC as independent auditor for 2026 and on a possible adjournment of the meeting if more time is needed to gather votes. As of April 24, 2026, 3,997,002 shares of common stock were outstanding and entitled to one vote per share.
SeaStar Medical Holding Corporation is asking stockholders to vote at its virtual 2026 annual meeting on four key items. Stockholders will elect one Class I director, John Neuman, to serve until the 2029 annual meeting, and vote on an expanded equity plan.
The company seeks approval to amend and restate its 2022 Equity Incentive Plan to increase authorized common shares under the plan from 207,046 to 896,546, following a 1-for-10 reverse stock split effective January 5, 2026. Stockholders will also vote on ratifying WithumSmith+Brown, PC as independent auditor for 2026 and on a possible adjournment of the meeting if more time is needed to gather votes. As of April 24, 2026, 3,997,002 shares of common stock were outstanding and entitled to one vote per share.
SeaStar Medical Holding Corporation is filing an S-1 to register the resale of up to 1,664,543 shares of common stock held by Lincoln Park Capital Fund LLC. These shares relate to a previously signed $15.0 million equity purchase agreement, under which SeaStar can periodically sell stock to Lincoln Park.
SeaStar will not receive proceeds from Lincoln Park’s resale of these registered shares, but may receive up to an additional $14,657,887.43 in gross proceeds from future share sales to Lincoln Park under the agreement. As of April 20, 2026, the company had 3,997,002 shares outstanding, and sales under this structure, alongside past at-the-market offerings, could dilute existing holders.
The filing also describes SeaStar’s commercial-stage inflammatory disease platform, including its FDA-approved pediatric SCD therapy under a Humanitarian Device Exemption, multiple Breakthrough Device Designations, and ongoing adult clinical programs targeting acute kidney injury and cardiorenal indications.
SeaStar Medical Holding Corporation is filing an S-1 to register the resale of up to 1,664,543 shares of common stock held by Lincoln Park Capital Fund LLC. These shares relate to a previously signed $15.0 million equity purchase agreement, under which SeaStar can periodically sell stock to Lincoln Park.
SeaStar will not receive proceeds from Lincoln Park’s resale of these registered shares, but may receive up to an additional $14,657,887.43 in gross proceeds from future share sales to Lincoln Park under the agreement. As of April 20, 2026, the company had 3,997,002 shares outstanding, and sales under this structure, alongside past at-the-market offerings, could dilute existing holders.
The filing also describes SeaStar’s commercial-stage inflammatory disease platform, including its FDA-approved pediatric SCD therapy under a Humanitarian Device Exemption, multiple Breakthrough Device Designations, and ongoing adult clinical programs targeting acute kidney injury and cardiorenal indications.
SeaStar Medical Holding Corporation reports that a previously filed federal securities class action against the company and certain executives has been dismissed with prejudice. The lawsuit, filed in 2024, had alleged misstatements or omissions related to the company’s business, operations and a prior financial restatement.
After the parties submitted a stipulation of dismissal on April 21, 2026, the United States District Court for the District of Colorado ordered on April 27, 2026 that the case be dismissed with prejudice. This ruling closes the putative class action without the option for the same claims to be refiled.
SeaStar Medical Holding Corporation reports that a previously filed federal securities class action against the company and certain executives has been dismissed with prejudice. The lawsuit, filed in 2024, had alleged misstatements or omissions related to the company’s business, operations and a prior financial restatement.
After the parties submitted a stipulation of dismissal on April 21, 2026, the United States District Court for the District of Colorado ordered on April 27, 2026 that the case be dismissed with prejudice. This ruling closes the putative class action without the option for the same claims to be refiled.
SeaStar Medical Holding Corporation reported much stronger 2025 results as it ramps commercialization of its QUELIMMUNE therapy. Net revenue rose to approximately $420 thousand in the fourth quarter from $67 thousand a year earlier, and to about $1.23 million for 2025 versus $135 thousand in 2024, reflecting a first full year of QUELIMMUNE sales and initial SCD research revenue. Quarterly net loss narrowed to roughly $2.9 million from $4.4 million, while full-year net loss improved to around $12.2 million from $24.8 million. Cash increased to $12.0 million as of December 31, 2025, compared with $1.8 million a year earlier. The company highlighted business progress, including adding top-ranked children’s hospitals to the QUELIMMUNE customer base, completing enrollment in the QUELIMMUNE SAVE pediatric post-marketing registry, surpassing the 50% enrollment milestone in the NEUTRALIZE-AKI pivotal trial in adults with acute kidney injury, and initiating a cardio-renal clinical trial using its Selective Cytopheretic Device therapy.
SeaStar Medical Holding Corporation reported much stronger 2025 results as it ramps commercialization of its QUELIMMUNE therapy. Net revenue rose to approximately $420 thousand in the fourth quarter from $67 thousand a year earlier, and to about $1.23 million for 2025 versus $135 thousand in 2024, reflecting a first full year of QUELIMMUNE sales and initial SCD research revenue. Quarterly net loss narrowed to roughly $2.9 million from $4.4 million, while full-year net loss improved to around $12.2 million from $24.8 million. Cash increased to $12.0 million as of December 31, 2025, compared with $1.8 million a year earlier. The company highlighted business progress, including adding top-ranked children’s hospitals to the QUELIMMUNE customer base, completing enrollment in the QUELIMMUNE SAVE pediatric post-marketing registry, surpassing the 50% enrollment milestone in the NEUTRALIZE-AKI pivotal trial in adults with acute kidney injury, and initiating a cardio-renal clinical trial using its Selective Cytopheretic Device therapy.
SeaStar Medical Holding Corp received an updated ownership report from investors Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. As of December 31, 2025, they report beneficial ownership of 3,980,665 shares of common stock, equal to 9.99% of the class.
The position is entirely through six warrants held by Intracoastal. Three warrants are counted, while three additional warrants are contractually blocked from exercise above 9.99% or 4.99% ownership caps. Without these blocker provisions, their beneficial ownership would be 5,342,845 shares. The group states the holdings are not for changing or influencing control of SeaStar Medical.
SeaStar Medical Holding Corp received an updated ownership report from investors Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. As of December 31, 2025, they report beneficial ownership of 3,980,665 shares of common stock, equal to 9.99% of the class.
The position is entirely through six warrants held by Intracoastal. Three warrants are counted, while three additional warrants are contractually blocked from exercise above 9.99% or 4.99% ownership caps. Without these blocker provisions, their beneficial ownership would be 5,342,845 shares. The group states the holdings are not for changing or influencing control of SeaStar Medical.